AKT1 and pituitary tumor: To date, everolimus (EVE) is the only PI3K/AKT/mTOR pathway inhibitor that has been studied in patients with aggressive pituitary tumors, with a total of seven documented cases (four AgPitNETS and three MetPitNET; three corticotrophs, one lactotroph and three of unknown histology) [12,90,91,92].